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Abstract
Background: Cognitive impairment is an important consequence of stroke and transient ischaemic attack, but its
determinants are not fully understood. Simple univariable or multivariable models have not shown clinical utility for
predicting cognitive impairment. Cardiovascular risk factors may influence cognition through multiple, direct, and
indirect pathways, including effects on prior cognition and stroke severity. Understanding these complex
relationships may help clinical teams plan intervention and follow-up strategies.
Methods: We analysed clinical and demographic data from consecutive patients admitted to an acute stroke ward.
Cognitive assessment comprised Abbreviated Mental Test and mini-Montreal Cognitive Assessment. We constructed
bias-corrected confidence intervals to test indirect effects of cardiovascular risk factors (hypertension, vascular
disease, atrial fibrillation, diabetes mellitus, previous stroke) on cognitive function, mediated through stroke severity
and history of dementia, and we assessed moderation effects due to comorbidity.
Results: From 594 eligible patients, we included 587 in the final analysis (age range 26–100; 45% female). Our
model explained R2 = 62.10% of variance in cognitive test scores. We found evidence for an indirect effect of
previous stroke that was associated with increased risk of prevalent dementia and in turn predicted poorer
cognitive score (estimate = − 0.39; 95% bias-corrected CI, − 0.75 to − 0.13; p = 0.02). Atrial fibrillation was associated
with greater stroke severity and in turn with a poorer cognitive score (estimate = − 0.27; 95% bias-corrected CI, −
0.49 to − 0.05; p = 0.02). Conversely, previous TIA predicted decreased stroke severity and, through that, lesser
cognitive impairment (estimate = 0.38; 95% bias-corrected CI, 0.08 to 0.75; p = 0.02). Through an association with
reduced stroke severity, vascular disease was associated with lesser cognitive impairment, conditional on presence
of hypertension and absence of diabetes mellitus (estimate = 0.36; 95% bias-corrected CI, 0.03 to 0.68; p = 0.02),
although the modelled interaction effects did not reach statistical significance.
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Conclusions: We have shown that relationships between cardiovascular risk factors and cognition are complex and
simple multivariable models may be overly reductionist. Including direct and indirect effects of risk factors, we
constructed a model that explained a substantial proportion of variation in cognitive test scores. Models that
include multiple paths of influence and interactions could be used to create dementia prognostic tools for use in
other healthcare settings.
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Background
Cognitive impairment is an important yet under-researched
complication of stroke and transient ischaemic attack
(TIA). It has been recognised as both common, with esti-
mates ranging up to even 96% [1], and highly relevant to
survivors’ outcomes, predicting decreased quality of life,
mood disorders, dependency, and mortality [2–4]. Features
of the stroke or TIA only partly explain the variation seen
in postmorbid cognitive function [5, 6]. Identifying other
outcome determinants could offer mechanistic insights into
cognitive decline, as well as improve risk stratification and
intervention planning. Prognosis of cognitive function fol-
lowing stroke or TIA is, however, difficult. Although many
multivariable prognostic models have been described, none
are yet considered suitable for clinical use.
In this context, cardiovascular diseases are of particular
interest, as they commonly co-occur in stroke populations
and can potentially be modified. Cardiovascular risk factors
are recognised as predictors of age-related cognitive decline
and dementia [7, 8], with associations being reported for dia-
betes mellitus, hypertension, coronary and peripheral vascu-
lar disease, atrial fibrillation, and previous stroke [9–11].
Often these factors pre-date incident stroke and so it seems
plausible that post-stroke cognitive impairment may be a
manifestation of prevalent vascular neurodegenerative pro-
cesses [5, 12]. However, the relationship of cardiovascular
diseases to post-stroke cognition is likely not only to be
driven by pre-stroke cognitive decline. Certain cardiovascular
risk factors are associated with stroke severity, which is in
turn a major determinant of cognitive outcome [13].
Intuitively, it seems that the presence of cardiovascular
risk factors should be consistently detrimental across out-
comes. For example, this seems to be the case for atrial
fibrillation, which is associated with both higher incidence
of dementia and greater stroke severity [14, 15]. However,
the cognitive effects of other cardiovascular risk factors
may be more complex, particularly where pathophysio-
logical processes trigger endogenous adaptive mecha-
nisms. For example, transient ischaemia can induce a state
of ischaemic tolerance or preconditioning that temporarily
(days to weeks) protects tissue from subsequent, persistent
ischaemia [16]. Evidence from observational studies sug-
gests that this phenomenon may occur in clinical practice.
Indeed, stroke preceded by TIA has been associated with
less severe symptoms, smaller infarct volumes, and better
functional outcomes [17–19].
A similar example relates to collateral circulation. The
presence of robust collaterals is also associated with
favourable post-stroke clinical outcomes, including an im-
proved response to thrombolytic and recanalisation therapy
[20, 21]. Yet collateral development is, in part, driven by a
pathological process, where chronic vascular disease leads
to subclinical ischaemia [22–24]. To add further complex-
ity, cardiovascular risk factors may not only co-occur but
also interact, affecting the manifestation of these putative
protective mechanisms. Findings from clinical and preclin-
ical models suggest that both hypertension and diabetes
may impair the development of collaterals [22, 25–29],
while diabetes also prevents ischaemic tolerance [30, 31].
Although many studies have investigated the effect of car-
diovascular risk factors on post-stroke cognition, results are
inconclusive or conflicting [6, 13]. The traditional approach
of using multivariable models can only identify those deter-
minants directly associated with an outcome, while
remaining relevant factors are held constant. Although in
some cases this approach is sufficient, it does not allow us
to explore the potential for multiple routes of predictor im-
pact, nor the interaction between co-occurring diseases. It
is possible that neutral results from previous research stem
from the duality or conditionality of the studied effects.
We aimed to investigate how cardiovascular risk factors
can affect cognitive function in the acute phase after
stroke, through influence on stroke severity and prior cog-
nitive impairment. We hypothesise that some effects may
be conditional (on presence vs absence of diabetes/hyper-
tension) and may differ depending on the path of influ-
ence, not only in strength, but also in direction. We
assume the latter may occur for prior TIA and vascular
disease, on the one hand associated with poorer cognitive
performance through increased risk of prevalent dementia,
while on the other potentially associated with improved
performance through alleviated stroke severity.
Methods
We conducted a secondary analysis of cross-sectional
data, collected from patients admitted to an urban teach-
ing hospital in the UK. The West of Scotland Research
Ethics Committee (16/WS/0001) approved the primary
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project, allowing inclusion of participants without the re-
quirement of providing written informed consent, data
collection being embedded in routine clinical care. We
based the design and conduct of the present study on rec-
ommendations from recent works, summarising theoret-
ical and practical approaches to development of mediation
and moderation models with an emphasis on best practice
[32, 33]. In reporting our study, we followed Strengthen-
ing the Reporting of Observational Studies in Epidemi-
ology (STROBE) guidelines [34].
Study setting and participants
The primary study involved recruitment of consecutive
patients admitted to a hyper-acute stroke unit. The unit
provides high dependency clinical care, accepting all
cases of suspected stroke and TIA, regardless of pread-
mission physical and cognitive function. Collection of
anonymised data took place in four waves: May 2016 to
February 2017, April to June 2017, October to December
2017, and July to August 2018. For the purpose of the
present study, we only included those patients where the
final consensus diagnosis by the clinical team was of
stroke or TIA.
Data collection
Five trained researchers used medical records and data
collected by the clinical team during acute admission to
extract information on basic demographics, pre-existing
medical conditions, and findings from neurological
examination. The researchers supplemented the clinical
and demographic data with cognitive data based on their
direct application of a standardised cognitive assessment
for all study participants.
Predictors
We included cardiovascular risk factors which have been
found to be associated with post-stroke cognitive func-
tion: vascular disease (peripheral and coronary), atrial
fibrillation, hypertension, diabetes mellitus, previous
stroke, and previous TIA. The clinical process in the
stroke service is for these data to be confirmed from at
least two data sources and includes information from
both primary and secondary care records. We coded all
risk factors as either present or absent. We also included
information on basic demographics of sex and age, the
latter treated as a continuous variable.
Mediators
In the primary study, stroke severity was assessed using
the National Institutes of Health Stroke Scale (NIHSS)
[35, 36]. Where a specific NIHSS score had not been
documented by the clinical team, NIHSS score was de-
rived based on findings from acute neurological examin-
ation described in patient notes [37]. As per emergency
department triage policy, these examinations are per-
formed immediately upon hospital admission and con-
firmed in the hyper-acute stroke unit, noting any
changes in initial symptoms (resolution or progression).
For inclusion in the analysis, we categorised NIHSS into
four groups: no stroke signs (score of 0), minor stroke
(score of 1 to 4), moderate stroke (score of 5 to 15), and
severe stroke (score of 16 to 42) [38].
The second mediator we included in the model was a
diagnosis of dementia prior to incident stroke or TIA.
Dementia diagnosis was taken from primary or second-
ary care medical records, including records from mental
health services. In the UK, dementia is diagnosed by sec-
ondary (specialist) care providers, based on the Inter-
national Classification of Diseases (ICD) criteria [39].
Cognitive outcome
Cognitive performance was assessed within a week of
stroke or TIA, using a short test battery of 13 items,
comprising Hodkinson’s Abbreviated Mental Test Score
(AMT-10) [40, 41] and a short form version of the Mon-
treal Cognitive Assessment (MoCA) [42]. The specific
tasks included in this measure have been described in a
previous publication [43].
For the purpose of this study, we considered outcome
data to be missing under three conditions: the patient
refused to participate; the patient was discharged prior
to assessment; the assessment was initiated but could
not be completed due to external circumstances, e.g. to
avoid disruption to activities carried out by the clinical
team. If a patient was unable to complete a particular
task due to an existing impairment (e.g. aphasia or limb
weakness), we assigned a score of zero for that item, in-
cluding it in the sum score [44]. In cases where the se-
verity of the patient’s condition (e.g. drowsiness,
agitation) prevented us from attempting the assessment
altogether, we used the approach of other acute screen-
ing tests, which is to assign an untestable status the low-
est score [45, 46]. Here, we assigned a score of − 1. This
approach minimises missing data and avoids exclusion
of patients with the most severe presentation. For ana-
lysis, we divided cognitive scores into quintiles, creating
the following groups: (1) scores from − 1 to 2, (2) scores
from 3 to 8, (3) scores from 9 to 11, (4) scores of 12 and
13, and (5) scores of 14 and 15.
Statistical analysis
We developed a first stage dual moderated mediation
model for prediction of cognitive performance, with two
parallel mediators—stroke severity and previous diagnosis
of dementia (Fig. 1). Although it was possible to model a
number of different interaction terms between included
predictors, we focused on three interactions most consist-
ently demonstrated by existing evidence [22, 25–31].
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Namely, we hypothesised that mediation of the effect of
vascular disease and previous TIA on the outcome
through stroke severity may be moderated by presence of
diabetes (in both cases) and hypertension (for vascular dis-
ease only).
Following initial results, we removed from the final
model the interaction term of TIA and diabetes mellitus
that is shown in this figure (arrow pointing from dia-
betes to arrow between previous TIA and stroke severi-
ty).As mediation analyses assume causal relationships,
we aimed to reflect the actual temporal order of occur-
rences in the model structure. This order was definite
for paths mediated by stroke severity (with cardiovascu-
lar risk factors present before the index stroke/TIA, and
the cognitive assessment carried out after) and seemed
plausible for paths mediated by dementia, with evidence
suggesting that cardiovascular diseases would have likely
developed in preceding stages of life.
We analysed our data within a path analysis frame-
work, using structural equation modelling software,
MPLUS version 8.3 [47]. Having an ordinal outcome of
interest, associations between variables were estimated
based on probit regression, using a robust weighted least
squares estimator (WLSMV). Missing data were handled
as per software default; cases with missing data on pre-
dictors were removed from the analysis, while missing
outcome data (here, including mediators) were treated
as a function of the observed predictors [48].
Steps involved in the moderated mediation analysis in-
cluded regressing cognitive performance on both media-
tors and the eight predictors, while each mediator was
regressed on the eight predictors. In line with our hy-
pothesis, we also regressed stroke severity on three inter-
action terms (TIA × diabetes mellitus, vascular disease ×
diabetes mellitus, vascular disease × hypertension). As
the selection of variables for the analysis was based on
research evidence, in order to avoid model overfitting,
we intended to retain all predictors and both mediators,
regardless of path significance. However, in order to
achieve a more parsimonious model, we planned to re-
move nonsignificant interaction terms [49]. We used es-
timates obtained through the regression analyses to
calculate indirect effects, applying a product of coeffi-
cients approach [33, 50].
For significant interaction terms, using the more com-
plex example of vascular disease, we intended to firstly
quantify the indices of partial mediated moderation; that
is, how much the effect of vascular disease on cognitive
performance through stroke severity changed depending
on the following: firstly, the presence or absence of dia-
betes mellitus when hypertension is absent (held fixed,
as all other predictors); secondly, the presence or ab-
sence of hypertension when diabetes mellitus is absent
[51]. We then probed the partial moderated mediation
effects to establish for what specific combination of fac-
tors (four options based on presence vs absence of dia-
betes and hypertension) vascular disease has a significant
conditional indirect effect on cognitive performance.
Based on the same principles, we planned to apply a
simplified version of this procedure to estimate the con-
ditional indirect effect of TIA depending on diabetes.
We determined the significance of individual paths
and indirect effects through constructing bias-corrected
bootstrap confidence intervals, based on drawing 1000
bootstrap samples. This method is recommended as it
does not assume normal sampling distribution and offers
greater precision for calculating confidence intervals
(CIs) compared to alternatives [52, 53]. Previous
Fig. 1 A conceptual diagram of the proposed dual moderated mediation model with two parallel mediators for acute cognitive performance
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bootstrapping studies have determined that in order to
detect even small mediation and moderated mediation
effects (estimate = 0.14) with 80% power, a sample of
nearly 500 participants is required [54, 55].
To provide information on the magnitude of mediated
effects, we calculated the proportion-mediated effect
size, a ratio of the specific indirect effect to the total ef-
fect of a predictor [56]. This is considered an intuitive
measure and is easily extrapolated from a simple to a
multi-mediator model [32]. Expecting an inconsistent
mediation model that is with direct and indirect effects
of some predictors being of opposite signs, we planned
to use absolute values of coefficients [57].
Recognising the potential bias from making assump-
tions about missing data, we repeated the described pro-
cedures in a sensitivity analysis, excluding participants
who due to an existing impairment did not complete
particular tasks for the cognitive assessment.
Results
A total of 703 patients were admitted during study recruit-
ment. From this sample, 109 were given a final diagnosis
other than stroke or TIA, leaving 594 participants fulfilling
inclusion criteria. Baseline characteristics are presented in
Table 1. A correlation matrix for included variables is pro-
vided in Additional file 1 (Table S1). As seven patients
had missing data on predictor variables, 587 participants
were included in the final analysis.
Final model structure and properties
Our initial model included three interaction terms.
However, preliminary results indicated that the inter-
action term of TIA and diabetes mellitus was not signifi-
cantly associated with stroke severity (p = 0.560) and so
we removed it from the model. As subsequent findings
suggested a trend for the remaining two interaction
terms, between vascular disease and diabetes mellitus
(p = 0.057) and vascular disease and hypertension (p =
0.056), we opted to retain them. Therefore, the final
model differed from that presented in Fig. 1 in only one
aspect, namely, we did not consider diabetes as a moder-
ator for the effect of TIA on stroke severity.
For this model, the chi-square statistic indicated no
significant discrepancy between the observed and
model-estimated covariance matrices: χ2 = 6.580, p =
0.254. Additional recommended fit indices confirmed
good model fit: Root Mean Square Error of Approxima-
tion (RMSEA) = 0.023, Comparative Fit Index (CFI) =
0.995, and Standardised Root Mean Square Residual
(SRMR) = 0.030 [58]. Overall, our model explained R2 =
62.10% of variance in cognitive test scores.
Table 1 Baseline characteristics of study sample
Variables
Age (years)
Range 26 to 100
Median (IQR) 72.0 (21.0)
Missing 2
Sex (female)
N (%) 269 (45.3%)
Missing 0
Previous stroke
N (%) 136 (22.9%)
Missing 0
Previous TIA
N (%) 40 (6.7%)
Missing 0
Hypertension
N (%) 316 (53.2%)
Missing 5
Vascular disease
N (%) 149 (25.1%)
Missing 5
Atrial fibrillation
N (%) 108 (18.2%)
Missing 5
Diabetes
N (%) 124 (20.9%)
Missing 5
Stroke severity (NIHSS score, range 0–42)
Range for sample 0 to 31
Median (IQR) 3.0 (1–5)
Categories
No stroke signs, N (%) 93 (16.1%)
Mild, N (%) 321 (55.4%)
Moderate, N (%) 128 (22.1%)
Severe, N (%) 37 (6.4%)
Missing 15
Prior dementia
N (%) 57 (9.6%)
Missing 0
Cognitive test score (range 0–15)
Range for testable participants 0 to 15
Median for testable participants (IQR) 11.0 (8–13)
Untestable patients, N (%) 101 (17.0%)
Missing 22
TIA transient ischaemic attack, NIHSS National Institutes of Health Stroke Scale
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Associations between predictors and mediators
More severe strokes were associated with age and atrial fib-
rillation, while severity decreased with a history of previous
TIA. The observed associations with interaction terms, just
above the threshold of statistical significance, suggested op-
posing effects of vascular disease, dependent on the pres-
ence of diabetes mellitus and hypertension. Co-occurring
with the former, it appeared potentially associated with
greater stroke severity, while co-occurring with the latter, it
appeared associated with less severe presentation. Predic-
tors of prior dementia included age and previous stroke.
We also observed a trend for an association between de-
mentia and history of vascular disease (p = 0.054).
Direct effects on cognitive performance
We found that both mediators were associated with acute
cognitive function: coefficient = − 0.748; 95% bias-corrected
CI, − 0.963 to − 0.572 for stroke severity; coefficient = −
0.720; 95% bias-corrected CI, − 1.096 to − 0.444 for demen-
tia. However, we observed no significant direct effects of
included predictors on cognitive performance (Table 2).
Indirect effects on cognitive performance
Effects mediated through stroke severity
We found that age had a negative specific indirect effect
on cognitive performance (Table 3), with 16.36% of the
absolute overall effect of age on cognition mediated by
stroke severity. Poorer cognitive outcome was also indir-
ectly associated with a history of atrial fibrillation, with a
proportion-mediated effect size of 57.45%. Conversely,
we observed improved cognitive performance through a
specific indirect effect of previous TIA, which consti-
tuted 49.68% of the absolute overall effect.
The indices of partial mediated moderation suggested
a trend for both estimated conditional indirect effects of
vascular disease on cognition through stroke severity
(p = 0.077 for both diabetes mellitus and hypertension).
Through probing, we observed that vascular disease pro-
duced a significant positive effect on performance under
only one condition, where there was a history of hyper-
tension without diabetes mellitus (estimate = 0.362; 95%
bias-corrected CI, 0.032 to 0.675; p = 0.024). The
proportion-mediated effect size was 30.37%.
Effects mediated through prior dementia
In relation to our second mediator, we found that previ-
ous stroke had a negative specific indirect effect on cogni-
tion, constituting 62.12% of the absolute overall effect.
Despite the observed trend for an association between de-
mentia and vascular disease, the specific indirect effect of
this risk factor on cognitive performance did not reach
statistical significance (p = 0.089). Age, therefore, was the
only predictor to exert a significant negative indirect effect
on cognition through both mediators. Compared to stroke
severity, dementia conveyed a considerably larger portion
of its overall absolute effect—78.18%.
Sensitivity analysis
For the sensitivity analysis, we excluded 38 participants
who due to impairments were not able to complete par-
ticular cognitive tasks. Estimates of direct and indirect
effects are presented in Additional file 1 (Tables S2 and
S3). Overall, the findings were similar to those presented
for the main analysis, with differences specifically relat-
ing to associations with dementia. Namely, we noted a
reversed situation for dementia predictors, where here
Table 2 Direct associations between predictors and stroke severity, dementia, and cognitive performance
Stroke severity (NIHSS) Prior dementia Cognitive performance
Unstandardised
coefficient
95% bias-
corrected CI
Unstandardised
coefficient
95% bias-
corrected CI
Unstandardised
coefficient
95% bias-
corrected CI
Age 0.012* 0.004–0.019 0.059* 0.039–0.078 0.003 − 0.016–0.027
Sex (female) − 0.031 − 0.210–0.180 − 0.098 − 0.458–0.248 − 0.264 − 0.588–0.046
Previous stroke 0.008 − 0.217–0.222 0.538* 0.176–0.932 0.230 − 0.129–0.649
Previous TIA − 0.512* − 0.934 to −
0.147
− 0.342 − 3.886–0.279 − 0.141 − 2.136–0.510
Atrial fibrillation 0.355* 0.075–0.609 0.145 − 0.270–0.554 − 0.092 − 0.464–0.279
Diabetes − 0.025 − 0.274–0.209 − 0.028 − 0.636–0.535 − 0.041 − 0.604–0.508
Hypertension 0.076 − 0.146–0.301 − 0.133 − 0.571–0.377 − 0.065 − 0.502–0.364
Vascular disease 0.002 − 0.405–0.374 0.611 − 0.051–1.246 0.390 − 0.178–1.127
Vascular disease ×
diabetes
0.466 − 0.031–0.924 – – – –
Vascular disease ×
hypertension
− 0.486 − 0.971–0.016 – – – –
TIA transient ischaemic attack, NIHSS National Institutes of Health Stroke Scale
*Significant at p < 0.05
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the association with vascular disease was statistically
significant and with previous stroke—at trend level (p =
0.056). Moreover, the indirect effect of previous stroke
on cognition through dementia did not reach statistical
significance (p = 0.080).
Discussion
Based on data from a real-world sample of stroke unit
inpatients, the results of our study supported the medi-
atory role of stroke severity and prior cognitive impair-
ment in the effects of specific cardiovascular risk factors
on acute cognition. Our analyses serve two purposes. By
using a complex approach to capture direct, indirect,
and interaction effects, we have created a model that
reasonably predicts cognition following stroke or TIA,
and may offer improvements on previous reductionist
multivariable analyses. Accurate prognostic tools could
improve clinical services, in particular allowing for better
informed intervention planning and follow-up. At a
methodological level, we have shown that attempts to
understand the relationship between cardiovascular risk
factors and cognition need to account for various life
course exposures that may interact in unexpected ways.
Some of our findings are in line with previously re-
ported associations and seem intuitively correct. Poorer
cognitive performance was associated with the following:
atrial fibrillation through increased stroke severity, previ-
ous stroke through increased risk of prevalent dementia,
and with age through both mediators. Importantly, how-
ever, our results also suggest novel associations. For ex-
ample, history of TIA and vascular disease—considered
risk factors for cognitive impairment—may in some
cases be associated with better acute cognitive perform-
ance through alleviating stroke severity.
Not all findings were consistent with our hypotheses.
Perhaps most interestingly, we observed that the likely
positive effect of vascular disease on cognition was con-
ditional on the simultaneous absence of diabetes and
history of hypertension. We assumed that the latter
would be detrimental, with previous studies showing
that high acute blood pressure, a state often seen in pa-
tients with chronic hypertension [59], is associated with
poorer prognosis after stroke [60]. It seems, therefore,
that the relationship between hypertension and post-
stroke outcomes may be indeed more complex than pre-
viously suggested. The authors of a recent clinical study
found that in cases of major stroke reperfusion, acute
high blood pressure was associated with better collateral
flow and thus decreased infarct growth and better clin-
ical outcomes, while the opposite was observed for pa-
tients without reperfusion [61].
It is also important to note that the indices of partial
mediated moderation did not reach statistical signifi-
cance, and so we cannot conclude that there is a differ-
ence in the effect of vascular disease between patients
with and without diabetes and hypertension. Moreover,
we did not have access to data relevant to explaining
mechanisms underlying analysed associations, for ex-
ample, on degree of carotid stenosis and extent of collat-
eral development, or time elapsed between previous TIA
and subsequent stroke or TIA.
Although our hypotheses were formulated in view of
potential endogenous adaptive processes, there are
plausible alternative explanations. Treatment effects,
which we were not able to control for, seem of particular
importance here. Specifically, research findings suggest
that aspirin, routinely administered following TIA, re-
duces the severity of early subsequent stroke [62], while
statins, prescribed in cases of vascular disease, enhance
collateral circulation [63, 64]. We were moreover unable
to adjust for the effects of education, not only relevant
to cognitive performance, but also associated with
Table 3 Indirect associations between predictors and cognitive performance
Effects mediated through stroke severity (NIHSS) Effects mediated through prior dementia
Unstandardised coefficient 95% bias-corrected CI Unstandardised coefficient 95% bias-corrected CI
Age − 0.009* − 0.015 to − 0.003 − 0.043* − 0.069 to − 0.024
Sex (female) 0.023 − 0.145–0.172 0.071 − 0.186–0.349
Previous stroke − 0.006 − 0.175–0.168 − 0.387* − 0.753 to − 0.130
Previous TIA 0.383* 0.083–0.745 0.247 − 0.218–2.152
Atrial fibrillation − 0.266* − 0.493 to − 0.052 − 0.105 − 0.479–0.202
Diabetes 0.019 − 0.161–0.207 0.020 − 0.398–0.516
Hypertension − 0.057 − 0.244–0.109 0.096 − 0.278–0.476
Vascular disease − 0.002 − 0.297–0.322 − 0.440 − 0.981–0.064
Vascular disease × diabetes − 0.349 − 0.748–0.030 – –
Vascular disease × hypertension 0.363 − 0.032–0.759 – –
TIA transient ischaemic attack, NIHSS National Institutes of Health Stroke Scale
*Significant at p < 0.05
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cardiovascular risk factor prevalence and outcomes [65].
These and other factors could be used to enhance future
models. We do not claim that our model is definitive,
but it allows to highlight the complex and sometimes
counterintuitive relationships between cardiovascular
risk factors and cognition.
Further study limitations relate to a retrospective as-
sessment of risk factors from medical case records, as it
is possible that relevant conditions had not been men-
tioned in notes or even diagnosed. We were also unable
to verify whether participants experienced milder forms
of cognitive impairment prior to incident stroke. Dichot-
omising into those cognitively intact and with a severe
form of impairment does not reflect the true, gradual
nature of cognitive deterioration. Finally, we did not
have access to information on longer-term cognitive out-
comes. Longitudinal studies have demonstrated consid-
erable individual changes in cognitive status between the
acute and chronic stages after stroke [4, 66, 67]. None-
theless, early post-stroke cognitive impairment has been
shown to be an important predictor of future patient
outcomes, both cognitive and functional [2], and in
healthcare settings, for many stroke survivors, the only
opportunity to undergo a cognitive screen may be dur-
ing hospital admission.
Strengths of our study include involving a sample rep-
resentative of a real-world stroke population, while
avoiding bias due to exclusion of patients with the most
severe impairments. At the same time, we conducted a
sensitivity analysis in a subgroup of participants with
complete cognitive data to reflect a more conservative
approach. We also strove to adhere to current best prac-
tice guidelines for design and conducting of mediation
and moderated mediation analyses.
Although we consider our results as preliminary, they
are not without clinical implications. Currently, there is
a lack of consensus guidelines on delivering assessments
and care focused on cognition following stroke or TIA
[68, 69]. Most stroke services have insufficient resources
to address these issues consistently for all patients, and
therefore, it is important to identify who is most likely
to experience cognitive impairment. Our study high-
lights the need to account for comorbidity and the po-
tential for risk factors not only to co-occur, but also to
interact. Although further confirmation is necessary, it
seems plausible that for patients with a history of TIA
and vascular disease with hypertension, the risk of cogni-
tive impairment could be underestimated, as they are
more likely to present with less severe strokes, while still
being prone to the progressive neurodegenerative effects
of these conditions, demonstrated in previous studies.
Taking into account that effects may differ in direction
depending on the path of influence is also an important
consideration for future studies, aiming to improve
outcome prognosis and investigate the detrimental role
of comorbidity, or the benefits of endogenous adaptive
mechanisms and disease management. We may also gain
a better understanding of associations by capturing milder
forms of cognitive decline. Finally, it seems important to
explore how the role of comorbidity in shaping cognitive
outcomes may change over time, particularly as the length
of life following stroke is increasing [70].
Conclusions
Our findings highlight the importance and complex na-
ture of relationships between cardiovascular diseases and
post-stroke cognition. They further add to the body of
evidence indicating the necessity to account for comor-
bidity when attempting to assess and understand cogni-
tive changes following stroke, in both clinical and
research contexts. In order to develop more precise
prognostic models of post-stroke cognitive outcome, fu-
ture studies should consider the potential for multiple
paths of influence and interactions between predictors.
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